Stewart W C, Stewart J A, Nelson L A, Kruft B
Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, USA.
Eur J Ophthalmol. 2008 Mar-Apr;18(2):199-204. doi: 10.1177/112067210801800206.
To evaluate physician use of prostaglandins (latanoprost, travoprost, and bimatoprost) in the United States (US) and Europe (EU).
One thousand multiple-choice surveys were distributed via e-mail in the US and EU.
The authors received 71 responses (US 40 [8%] and EU 31 [6%]). Physicians preferred prostaglandin monotherapy (US 39 [98%] and EU 22 [71%], p=0.003), usually latanoprost (US 32 [80%] and EU 22 [71%], p=0.45). When more efficacy was required, US physicians would typically switch (23 [58%]) and EU physicians would add therapy (22 [71%], p=0.007). In both continents 45% of respondents stated bimatoprost was more efficacious.
US and EU physicians prefer prostaglandin monotherapy, most commonly latanoprost. Bimatoprost is often perceived as more effective, but having a higher incidence of conjunctival hyperemia.
评估美国和欧洲医生对前列腺素（拉坦前列素、曲伏前列素和比马前列素）的使用情况。
通过电子邮件在美国和欧洲分发了1000份多项选择题调查问卷。
作者共收到71份回复（美国40份[8%]，欧洲31份[6%]）。医生更倾向于前列腺素单药治疗（美国39份[98%]，欧洲22份[71%]，p = 0.003），通常选择拉坦前列素（美国32份[80%]，欧洲22份[71%]，p = 0.45）。当需要更高疗效时，美国医生通常会换药（23份[58%]），而欧洲医生会增加联合治疗（22份[71%]，p = 0.007）。在两大洲，45%的受访者表示比马前列素疗效更佳。
美国和欧洲的医生更倾向于前列腺素单药治疗，最常用的是拉坦前列素。比马前列素通常被认为疗效更佳，但结膜充血发生率较高。
